Management of a Patient with Pancreatic Mass with Metastasis and Leaking Aorta

Immediate Management of Leaking Aorta

The European Society of Cardiology recommends that CT scan with non-contrast phase followed by contrast injection should be performed immediately to evaluate the extent of the aortic leak and to differentiate between contained rupture and free rupture 1
Imaging should cover the entire aorta, iliac, and femoral arteries to provide sufficient information for planning surgical or endovascular treatment, with a mortality rate of up to 76% at 24 hours after the initial event 1
Contained rupture presents with acute chest/back pain while maintaining hemodynamic stability, whereas free rupture typically leads rapidly to internal bleeding and death, with a 30-day mortality rate of approximately 19% for endovascular repair and 33% for open surgical repair 1

The American Society of Clinical Oncology recommends a multiphase CT scan of chest, abdomen, and pelvis to assess the extent of disease, and careful evaluation of the patient's performance status, symptom burden, and comorbidity profile for treatment planning 2, 3
For patients with ECOG PS 0-1 and favorable comorbidity profile, FOLFIRINOX is recommended as first-line therapy, with a 5-year overall survival of approximately 2% 2, 3
For patients with ECOG PS 2 or significant comorbidities, gemcitabine alone is recommended, with the addition of capecitabine or erlotinib considered on a case-by-case basis 2, 3

The American Society of Clinical Oncology recommends consideration of neurolytic celiac plexus block for pain management, which provides better pain control and reduces opioid consumption 5
Nutritional support, including consultation with a nutritionist/dietician and pancreatic enzyme replacement therapy, is essential for patients with exocrine insufficiency 6, 7
Endoscopic placement of self-expanding metal stents is recommended for management of biliary obstruction, with metal stents generally preferred over plastic stents 8, 9
Primary prophylaxis with low-molecular-weight heparins is considered for high-risk patients to prevent venous thromboembolism, which has one of the highest incidences among malignancies 9, 7